OKI-179 + binimetinib
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
RAS Mutation
Conditions
RAS Mutation, NRAS Gene Mutation, Melanoma
Trial Timeline
May 11, 2022 → Jan 29, 2025
NCT ID
NCT05340621About OKI-179 + binimetinib
OKI-179 + binimetinib is a phase 1/2 stage product being developed by OnKure Therapeutics for RAS Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT05340621. Target conditions include RAS Mutation, NRAS Gene Mutation, Melanoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05340621 | Phase 1/2 | Completed |
Competing Products
20 competing products in RAS Mutation